Lasix (Furosemide) Should Generally Be Avoided in Newborns with Patent Ductus Arteriosus
Furosemide is contraindicated or should be avoided in premature newborns with PDA, particularly when used alongside COX inhibitors (indomethacin/ibuprofen), as it increases the risk of acute renal failure without improving ductal closure rates and may actually increase the risk of PDA persistence in the first weeks of life.
Critical FDA Warning
The FDA label explicitly warns that in premature neonates with respiratory distress syndrome, diuretic treatment with furosemide in the first few weeks of life may increase the risk of persistent patent ductus arteriosus (PDA), possibly through a prostaglandin-E-mediated process 1. This is a fundamental contraindication to routine use.
Evidence Against Furosemide Use
When Combined with COX Inhibitors (Indomethacin/Ibuprofen)
Furosemide significantly increases acute renal failure risk (RR 4.96,95% CI: 1.80-13.6) when given during COX inhibitor therapy, without reducing PDA closure failure or mortality 2
In infants receiving indomethacin with furosemide pretreatment (1 mg/kg IV before each dose), there was a significant 50% increase in serum creatinine (vs. 18% in controls, p<0.05) and significant hyponatremia (-9 vs. -3 mmol/L, p<0.05) at 72-96 hours, without any increase in urine output 3
Furosemide does not prevent indomethacin-related toxicity and may actually worsen outcomes in dehydrated infants (BUN/creatinine ratio >20 mg/mg), where it causes undesired 5% weight loss 4
Mechanism of Harm
Furosemide increases prostaglandin E2 production in the kidneys 5, which directly counteracts the mechanism by which indomethacin/ibuprofen close the PDA (prostaglandin synthesis inhibition). This creates a pharmacologic conflict that worsens renal function without benefit.
Additional FDA Safety Concerns
- Nephrocalcinosis/nephrolithiasis: Renal calcifications have occurred in severely premature infants treated with IV furosemide for edema due to PDA 1
- Ototoxicity risk: Premature infants with post-conceptual age <31 weeks receiving doses >1 mg/kg/24 hours may develop toxic plasma levels associated with hearing loss 1
- Monitor renal function and consider renal ultrasonography in pediatric patients receiving furosemide 1
When Furosemide Might Be Considered (Rare Exceptions)
If pulmonary edema from a hemodynamically significant PDA requires diuresis:
- Only use if NOT concurrently treating with COX inhibitors (avoid the prostaglandin conflict)
- Ensure adequate hydration (BUN/creatinine ratio <20 mg/mg) - furosemide is contraindicated in dehydrated infants 4
- Dose: Keep below 1 mg/kg/24 hours in infants <31 weeks post-conceptual age 1
- Monitor closely: Serum creatinine, electrolytes (especially sodium), urine output, weight, and renal ultrasound
- Consider concurrent chlorothiazide to decrease hypercalcinuria 1
Common Pitfalls to Avoid
- Do not routinely give furosemide with indomethacin/ibuprofen - this combination worsens renal function without benefit 2, 3
- Do not use in dehydrated infants - furosemide causes further weight loss and electrolyte derangement 4
- Do not exceed 1 mg/kg/24 hours in very premature infants - risk of ototoxicity 1
- Do not use in the first weeks of life for PDA management - increases risk of PDA persistence 1
Alternative Approach
Focus on conservative fluid management rather than diuretics for hemodynamically significant PDA 5. If pharmacologic closure is needed, use COX inhibitors alone without furosemide 2, 4.